Download PDF
Thromb Haemost 2009; 101(02): 373-380
DOI: 10.1160/TH08-01-0025
Cellular Proteolysis and Oncology
Schattauer GmbH

Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11

Hellinida Thomadaki
1   Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Panepistimiopolis, Athens, Greece
,
Konstantinos Mavridis
1   Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Panepistimiopolis, Athens, Greece
,
Maroulio Talieri
2   “G. Papanicolaou” Research Center of Oncology “Saint Savas” Hospital Athens, Greece
,
Andreas Scorilas
1   Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Panepistimiopolis, Athens, Greece
› Author AffiliationsFinancial support: This work was supported by a Greek-Czech joint research and technology grant (EPAN.M.4.3.6.1) co-funded by the European Regional Development Fund (70%) and National Resources (30%) – Ministry of Development – General Secretariat for Research & Technology of Greece and by the Biopaths Co.
Further Information

Publication History

Received: 13 January 2008

Accepted after major revision: 01 January 2008

Publication Date:
23 November 2017 (online)

    Permissions and Reprints

Summary

Several of the novel kallikrein-related peptidases (tissue kallikreins; KLKs) are emerging new serum and/or tissue biomarkers for prostate cancer (CaP) diagnosis, prognosis and monitoring. In the present research approach, our objective was to investigate the possible alterations in the mRNA expression levels of KLK5 and KLK11 genes in prostate cancer cells PC3 as a response to treatment with Mitoxantrone, Etoposide, Doxorubicin and Carboplatin. Viability was assessed with the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay after cell treatment with either mitoxantrone (2 μM), etoposide (20 μM), doxorubicin (1 μM), or carboplatin (15 μM), for 24, 48 and 72 hours. Additionally, trypan blue staining revealed that in PC3 cells all drugs displayed almost the same limited necrotic effects which appeared mainly at 72 hours of treatment. PC3 prostate cancer cells showed a concentration- and time-dependent increased cytotoxicity to the drugs under study which was mainly due to reduction of cell proliferation efficiency. Distinct modulations of KLK5 and KLK11 genes, at the mRNA level, were observed, supporting a drug-dependent cell response. Our experimental data demonstrate that the molecular profile mainly of KLK5 gene may serve as a new potential molecular biomarker predicting treatment response in CaP cells.

Keywords

Kallikrein-related peptidases - kallikreins - KLK11 - KLK5 - prostate cancer - PC3 - cytotoxic drugs - mitoxantrone - etoposide - doxorubicin - carboplatin
 

  • References

  • 1 Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006; 11: 1388-1413.
    CrossrefPubMedGoogle Scholar
  • 2 Reynolds MA, Kastury K, Groskopf J. et al. Molecular markers for prostate cancer. Cancer Lett 2007; 249: 5-13.
    CrossrefPubMedGoogle Scholar
  • 3 Rubin MA, De Marzo AM. Molecular genetics of human prostate cancer. Mod Pathol 2004; 17: 380-388.
    CrossrefPubMedGoogle Scholar
  • 4 Nelson WG, Yegnasubramanian S, Agoston AT. et al. Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci 2007; 12: 4254-4266.
    CrossrefPubMedGoogle Scholar
  • 5 Shand RL, Gelmann EP. Molecular biology of prostate-cancer pathogenesis. Curr Opin Urol 2006; 16: 123-131.
    CrossrefPubMedGoogle Scholar
  • 6 Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006; 99: 333-344.
    CrossrefPubMedGoogle Scholar
  • 7 Richter E, Srivastava S, Dobi A. Androgen receptor and prostate cancer. Prostate Cancer Prostatic Dis 2007; 10: 114-118.
    CrossrefPubMedGoogle Scholar
  • 8 Collins AT, Maitland NJ. Prostate cancer stem cells. Eur J Cancer 2006; Jun 42 (09) 1213-8.
    CrossrefPubMedGoogle Scholar
  • 9 Bradford TJ, Tomlins SA, Wang X. et al. Molecular markers of prostate cancer. Urol Oncol 2006; 24: 538-551.
    CrossrefPubMedGoogle Scholar
  • 10 Magklara A, Scorilas A, Catalona WJ, Diamandis EP. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem, 1999; 45: 1960-1966.
    PubMedGoogle Scholar
  • 11 Yousef GM, Chang A, Scorilas A, Eleftherios P. Diamandis. Genomic organization of the human kallikrein locus on chromosome 19q13.3-q13.4. Biochem Bioph Res Commun, 2000; 276: 125-133.
    CrossrefPubMedGoogle Scholar
  • 12 Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004; 2: 257-280.
    PubMedGoogle Scholar
  • 13 Kurlender L, Borgono C, Michael IP. et al. A survey of alternative transcripts of human tissue kallikrein genes. Biochim Biophys Acta 2005; 1755: 1-14.
    PubMedGoogle Scholar
  • 14 Hooley E, McEwan PA, Emsley J. Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation. J Thromb Haemost 2007; 5: 2461-2466.
    CrossrefPubMedGoogle Scholar
  • 15 Schmaier AH, McCrae KR. The plasma kallikreinkinin system: its evolution from contact activation. J Thromb Haemost 2007; 5: 2323-2329.
    CrossrefPubMedGoogle Scholar
  • 16 Yousef GM, Diamandis EP. Expanded human tissue kallikrein family--a novel panel of cancer biomarkers. Tumour Biol. 2002; 23: 185-192.
    CrossrefPubMedGoogle Scholar
  • 17 Obiezu CV, Diamandis EP. Human tissue kallikrein gene family: applications in cancer. Cancer Lett 2005; 224: 1-22.
    CrossrefPubMedGoogle Scholar
  • 18 Paliouras M, Borgono C, Diamandis EP. Human tissue kallikreins: the cancer biomarker family. Cancer Lett 2007; 249: 61-79.
    CrossrefPubMedGoogle Scholar
  • 19 Yousef GM, Diamandis EP. Human tissue kallikreins: a new enzymatic cascade pathway?. Biol Chem 2002; 383: 1045-1057.
    PubMedGoogle Scholar
  • 20 Yousef GM, Eleftherios PD. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocrine Rev 2001; 22: 184-204.
    PubMedGoogle Scholar
  • 21 Yousef GM, Scorilas A, Diamandis EP. Genomic organization, mapping, tissue expression and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kallikrein gene family. Genomics 2000; 63: 88-96.
    CrossrefPubMedGoogle Scholar
  • 22 Stavropoulou P, Gregorakis AK, Plebani M. et al. Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. Clin Chim Acta 2005; 357: 190-195.
    CrossrefPubMedGoogle Scholar
  • 23 Nakamura T, Mitsui S, Okui A. et al. Alternative splicing isoforms of hippostasin [PRSS20/KLK11] in prostate cancer cell lines. Prostate 2001; 49: 72-78.
    CrossrefPubMedGoogle Scholar
  • 24 Nakamura T, Stephan C, Scorilas A. et al. Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. Urology 2003; 61: 1042-1046.
    CrossrefPubMedGoogle Scholar
  • 25 Borgono CA, Fracchioli S, Yousef GM. et al. Favorable prognostic value of tissue human kallikrein 11 [hK11] in patients with ovarian carcinoma. Int J Cancer 2003; 106: 605-610.
    CrossrefPubMedGoogle Scholar
  • 26 Shigemasa K, Gu L, Tanimoto H. et al. Human kallikrein gene 11 [KLK11] mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer. Clin Cancer Res 2004; 10: 2766-2770.
    CrossrefPubMedGoogle Scholar
  • 27 Petraki CD, Papanastasiou PA, Karavana VN. et al. Cellular distribution of human tissue kallikreins: immunohistochemical localization. Biol Chem 2006; 387: 653-663.
    PubMedGoogle Scholar
  • 28 Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007; 53: 1423-1432.
    CrossrefPubMedGoogle Scholar
  • 29 Yousef GM, Diamandis EP. The new kallikrein-like gene, KLK-L2. Molecular characterization, mapping, tissue expression, and hormonal regulation. J Biol Chem 1999; 274: 37511-37516.
    CrossrefPubMedGoogle Scholar
  • 30 Yousef GM, Scorilas A, Kyriakopoulou LG. et al. Human kallikrein gene 5 [KLK5] expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. Clin Chem 2002; 48: 1241-1250.
    PubMedGoogle Scholar
  • 31 Shinoda Y, Kozaki K, Imoto I. et al. Association of KLK5 overexpression with invasiveness of urinary bladder carcinoma cells. Cancer Sci 2007; 98: 1078-1086.
    CrossrefPubMedGoogle Scholar
  • 32 Kim H, Scorilas A, Katsaros D. et al. Human kallikrein gene 5 [KLK5] expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer 2001; 84: 643-650.
    CrossrefPubMedGoogle Scholar
  • 33 Luo LY, Yousef G, Diamandis EP. Human tissue kallikreins and testicular cancer. APMIS 2003; 111 (01) 225-32 discussion 32-33.
    CrossrefPubMedGoogle Scholar
  • 34 Planque C, de Monte M, Guyetant S. et al. KLK5 and KLK7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer. Biochem Biophys Res Commun 2005; 329: 1260-1266.
    CrossrefPubMedGoogle Scholar
  • 35 Yousef GM, Scorilas A, Chang A. et al. Down-regulation of the human kallikrein gene 5 [KLK5] in prostate cancer tissues. Prostate 2002; 51: 126-32.
    CrossrefPubMedGoogle Scholar
  • 36 Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
    CrossrefPubMedGoogle Scholar
  • 37 Freshney R. Culture of Animal Cells: A Manual of Basic Techniqu. Alan R. Liss, Inc.; New York: 1987. pp 117.
    Google Scholar
  • 38 Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990; 40: 2353-2362.
    CrossrefPubMedGoogle Scholar
  • 39 Fleming MT, Morris MJ, Heller G. et al. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol 2006; 3: 658-67.
    PubMedGoogle Scholar
  • 40 Cheung R, Tucker SL, Kuban DA. First-year PSA kinetics and minima after prostate cancer radiotherapy are predictive of overall survival. Int J Radiat Oncol Biol Phys 2006; 66: 20-4.
    CrossrefPubMedGoogle Scholar
  • 41 Keetch DW, Andriole GL, Ratliff TL. et al. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting. Urology 1997; 50: 901-5.
    CrossrefPubMedGoogle Scholar
  • 42 Crook J, Gillan C, Yeung I. et al. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys 2007; 69: 426-33.
    CrossrefPubMedGoogle Scholar
  • 43 McLean M, McGowan TS, Catton CN. et al. The impact of prostatic manipulation upon serum PSA in patients with adenocarcinoma of the prostate. Clin Oncol (R Coll Radiol) 1993; 5: 293-6.
    CrossrefPubMedGoogle Scholar
  • 44 Sridhara R, Eisenberger MA, Sinibaldi VJ. et al. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 1995; 13: 2944-53.
    CrossrefPubMedGoogle Scholar
  • 45 Boland MP, Fitzgerald KA, O’Neill LA. Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells. J Biol Chem 2000; 275: 25231-25238.
    CrossrefPubMedGoogle Scholar
  • 46 Harker WG, Slade DL, Drake FH, Parr RL. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 1991; 30: 9953-9961.
    CrossrefPubMedGoogle Scholar
  • 47 van Maanen JM, Retel J, de Vries J, Pinedo HM. Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst 1988; 80: 1526-1533.
    CrossrefPubMedGoogle Scholar
  • 48 Dwarakanath BS, Khaitan D, Mathur R. Inhibitors of topoisomerases as anticancer drugs: problems and prospects. Indian J Exp Biol 2004; 42: 649-659.
    PubMedGoogle Scholar
  • 49 Baldwin EL, Osheroff N. Etoposide, topoisomerase II and cancer. Curr Med Chem Anti-Cancer Agents 2005; 5: 363-372.
    CrossrefPubMedGoogle Scholar
  • 50 Bose RN. Biomolecular targets for platinum antitumor drugs. Mini Rev Med Chem 2002; 2: 103-111.
    CrossrefPubMedGoogle Scholar
  • 51 Floros KV, Thomadaki H, Lallas G, Katsaros N, Talieri M, Scorilas A. Cisplatin-induced apoptosis in HL-60 human promyelocytic leukaemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12. Ann NY Acad Sci 2003; 1010: 153-158.
    CrossrefPubMedGoogle Scholar
  • 52 Floros KV, Thomadaki H, Katsaros N, Talieri M, Scorilas A. mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem 2004; 385: 1099-1103.
    PubMedGoogle Scholar
  • 53 Floros KV, Talieri M, Scorilas A. Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Biol Chem 2006; 387: 1629-1633.
    PubMedGoogle Scholar
  • 54 Huang R, Wallqvist A, Covell DG. Anticancer metal compounds in NCI’s tumor-screening database: putative mode of action. Biochem Pharmacol 2005; 69: 1009-1039.
    CrossrefPubMedGoogle Scholar
  • 55 Hortobagyi GN. Chemotherapy of breast cancer: a historical perspective. Semin Oncol 1997; 17: S1-S4.
    PubMedGoogle Scholar